Autologous Plasma Rich in Growth Factors for Severe Dry Eye Disease

The goal of this clinical trial is to evaluate the change in dry eye symptoms after the treatment with Plasma Rich in Growth Factors (PRGF) in patients with severe dry eye. The main question it aims to answer is: Are dry eye simptoms less after the treatment with PRGF? Researchers will compare standard topical treatment and PRGF with standard topical treatment and placebo to see if there is a difference in dry eye symptoms between arms. Secondary outcomes include changes in tear meniscus height, non invasive tear break-up time, conjunctival hyperemia, meibomian gland dropout and Ocular Staining Score (OSS) scale for corneal and conjunctival damage. Participants will be asked to use standard treatment and PRGF or placebo for 1 month.

Inclusion Criteria: * Any male or female patient over 18 years of age with severe dry eye disease who is prescribed PRGF treatment and presents for consultation between august 2026 and august 2027. * Acceptance to participate in the study and signing of the informed consent form Exclusion Criteria: * Platelet disorders or coagulation abnormalities. * Active systemic infection.